- Home
- HOWL vs BEAT Comparison
HOWL vs BEAT Comparison
Compare HOWL & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- BEAT
- Stock Information
- Founded
- HOWL 2017
- BEAT 2015
- Country
- HOWL United States
- BEAT United States
- Employees
- HOWL N/A
- BEAT N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- HOWL Health Care
- BEAT Technology
- Exchange
- HOWL Nasdaq
- BEAT Nasdaq
- Market Cap
- HOWL 87.4M
- BEAT 74.1M
- IPO Year
- HOWL 2021
- BEAT 2021
- Fundamental
- Price
- HOWL $1.41
- BEAT $2.46
- Analyst Decision
- HOWL Strong Buy
- BEAT Buy
- Analyst Count
- HOWL 2
- BEAT 1
- Target Price
- HOWL $9.50
- BEAT $8.00
- AVG Volume (30 Days)
- HOWL 280.2K
- BEAT 110.4K
- Earning Date
- HOWL 03-06-2025
- BEAT 03-19-2025
- Dividend Yield
- HOWL N/A
- BEAT N/A
- EPS Growth
- HOWL N/A
- BEAT N/A
- EPS
- HOWL N/A
- BEAT N/A
- Revenue
- HOWL $3,386,000.00
- BEAT N/A
- Revenue This Year
- HOWL N/A
- BEAT N/A
- Revenue Next Year
- HOWL $34.17
- BEAT N/A
- P/E Ratio
- HOWL N/A
- BEAT N/A
- Revenue Growth
- HOWL N/A
- BEAT N/A
- 52 Week Low
- HOWL $1.26
- BEAT $1.35
- 52 Week High
- HOWL $8.19
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- HOWL 41.51
- BEAT 51.07
- Support Level
- HOWL $1.28
- BEAT $2.19
- Resistance Level
- HOWL $1.42
- BEAT $2.41
- Average True Range (ATR)
- HOWL 0.09
- BEAT 0.14
- MACD
- HOWL 0.01
- BEAT 0.04
- Stochastic Oscillator
- HOWL 49.93
- BEAT 66.67
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.